Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

BACKGROUND: Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial. OBJECTIVE: To evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lear, J.T., Migden, M.R., Lewis, K.D., Chang, A.L.S., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, M., Zhou, J., Trefzer, U., Kaatz, M., Loquai, C., Kudchadkar, R., Sellami, D., Dummer, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873455/
https://www.ncbi.nlm.nih.gov/pubmed/28846163
http://dx.doi.org/10.1111/jdv.14542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873455/
https://www.ncbi.nlm.nih.gov/pubmed/28846163
http://dx.doi.org/10.1111/jdv.14542

Ejemplares similares